Last update Jan. 15, 2021

1-{4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonyl}-3-cyclohexylurea

Compatible

Safe substance and/or breastfeeding is the best option.

Sulfonylurea that stimulates endogenous insulin secretion. May cause hypoglycemia.
Indicated in the treatment of type 2 diabetes.
Oral administration in one dose a day.

Its pharmacokinetic data (moderately high molecular weight, very high percentage of plasma protein binding and high volume of distribution) explain the zero or negligible passage into breast milk observed (Feig 2005).
The infants' blood glucose levels were normal (Feig 2005).

Experts authors consider the use of this medication to be safe during breastfeeding (Serrano 2015, Rowe 2013, Refuerzo 2011, Glatstein 2009, Feig 2007).
List of WHO essential medicines: compatible with breastfeeding (WHO / UNICEF 2002).

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

1-{4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonyl}-3-cyclohexylurea is Glibenclamide in Chemical name.

Is written in other languages:

1-{4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonyl}-3-cyclohexylurea is also known as

Group

1-{4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonyl}-3-cyclohexylurea belongs to this group or family:

Tradenames

Main tradenames from several countries containing 1-{4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonyl}-3-cyclohexylurea in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 70 - 84 %
Molecular weight 494 daltons
Protein Binding 99.9 %
VD 0.67 l/Kg
pKa 4.32 -
Tmax 1.3 - 4 hours
3.3 - 13.9 hours
M/P ratio ≈ 0 -
Theoretical Dose < 0.0007 mg/Kg/d
Relative Dose < 1 %

References

  1. Sanofi-aventis. Glibenclamida- Ficha técnica. 2017 Full text (in our servers)
  2. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  3. Teva. Glyburide. Drug Summary. 2013 Full text (in our servers)
  4. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  5. Refuerzo JS. Oral hypoglycemic agents in pregnancy. Obstet Gynecol Clin North Am. 2011 Abstract
  6. Glatstein MM, Djokanovic N, Garcia-Bournissen F, Finkelstein Y, Koren G. Use of hypoglycemic drugs during lactation. Can Fam Physician. 2009 Abstract Full text (link to original source) Full text (in our servers)
  7. Feig DS, Briggs GG, Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann Pharmacother. 2007 Abstract
  8. Feig DS, Briggs GG, Kraemer JM, Ambrose PJ, Moskovitz DN, Nageotte M, Donat DJ, Padilla G, Wan S, Klein J, Koren G. Transfer of glyburide and glipizide into breast milk. Diabetes Care. 2005 Abstract Full text (link to original source) Full text (in our servers)
  9. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)

Total visits

1,028

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM